Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2016

Open Access 01-12-2016 | Original research

Pharmacokinetic modeling of [18F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds

Authors: Kitiwat Khamwan, Donika Plyku, Shannon E. O’Reilly, Alison Goodkind, Xinhua Cao, Frederic H. Fahey, S. Ted Treves, Wesley E. Bolch, George Sgouros

Published in: EJNMMI Research | Issue 1/2016

Login to get access

Abstract

Background

Absorbed dose estimates for pediatric patients require pharmacokinetics that are, to the extent possible, age-specific. Such age-specific pharmacokinetic data are lacking for many of the diagnostic agents typically used in pediatric imaging. We have developed a pharmacokinetic model of [18F]fluorodeoxyglucose (FDG) applicable to premature infants and to 0- (newborns) to 5-year-old patients, which may be used to generate model-derived time-integrated activity coefficients and absorbed dose calculations for these patients.

Methods

The FDG compartmental model developed by Hays and Segall for adults was fitted to published data from infants and also to a retrospective data set collected at the Boston Children’s Hospital (BCH). The BCH data set was also used to examine the relationship between uptake of FDG in different organs and patient weight or age.

Results

Substantial changes in the structure of the FDG model were required to fit the pediatric data. Fitted rate constants and fractional blood volumes were reduced relative to the adult values.

Conclusions

The pharmacokinetic models developed differ substantially from adult pharmacokinetic (PK) models which can have considerable impact on the dosimetric models for pediatric patients. This approach may be used as a model for estimating dosimetry in children from other radiopharmaceuticals.
Appendix
Available only for authorised users
Literature
1.
Schauer DA, Linton OW. NCRP report No. 160, ionizing radiation exposure of the population of the United States, medical exposure—are we doing less with more, and is there a role for health physicists? Health Phys. 2009;97(1):1–5.CrossRefPubMed
2.
Hricak H, Brenner DJ, Adelstein SJ, Frush DP, Hall EJ, Howell RW, et al. Managing radiation use in medical imaging: a multifaceted challenge. Radiology. 2011;258(3):889–905.CrossRefPubMed
3.
Mettler FAJ, Thomadsen BR, Bhargavan M, Gilley DB, Gray JE, Lipoti JA, et al. Medical radiation exposure in the US in 2006: preliminary results. Health Phys. 2008;95(5):502–7.CrossRefPubMed
4.
National Research Council. Health risks from exposure to low levels of ionizing radiation: BEIR VII—phase 2. Washington, DC: National Research Council; 2005.
5.
ICRP. Publication 103: the 2007 recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007;37(2-4):1–332.CrossRef
6.
Lassmann M, Treves ST. Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5. 2008) and the 2010 North American consensus guidelines. Eur J Nucl Med Mol Imaging. 2014;41(5):1036–41.CrossRefPubMed
7.
Treves ST, Lassmann M. International guidelines for pediatric radiopharmaceutical administered activities. J Nucl Med. 2014;55(6):869–70.CrossRefPubMed
8.
Lassmann M, Biassoni L, Monsieurs M, Franzius C. The new EANM paediatric dosage card: additional notes with respect to F-18. Eur J Nucl Med Mol Imaging. 2008;35(9):1666–8.CrossRefPubMed
9.
Lassmann M, Biassoni L, Monsieurs M, Franzius C, Jacobs F. The new EANM paediatric dosage card. Eur J Nucl Med Mol Imaging. 2007;34(5):796–8.CrossRefPubMed
10.
Sgouros G, Frey EC, Bolch WE, Wayson MB, Abadia AF, Treves ST. An approach for balancing diagnostic image quality with cancer risk: application to pediatric diagnostic imaging of 99mTc-dimercaptosuccinic acid. J Nucl Med. 2011;52(12):1923–9.CrossRefPubMedPubMedCentral
11.
Alessio AM, Sammer M, Phillips GS, Manchanda V, Mohr BC, Parisi MT. Evaluation of optimal acquisition duration or injected activity for pediatric 18F-FDG PET/CT. J Nucl Med. 2011;52(7):1028–34.CrossRefPubMed
12.
ICRP. Publication 53: radiation dose to patients from radiopharmaceuticals. Ann ICRP. 1988;18(1-4):1–377.
13.
ICRP. Publication 106: radiation dose to patients from radiopharmaceuticals: addendum 3 to ICRP publication 53. Ann ICRP. 2008;38(1-2):1–197.CrossRefPubMed
14.
Hua C, Merchant TE, Li X, Li Y, Shulkin BL. Establishing age-associated normative ranges of the cerebral 18F-FDG uptake ratio in children. J Nucl Med. 2015;56(4):575–9.CrossRefPubMed
15.
Ruotsalainen U, Suhonen-Polvi H, Eronen E, Kinnala A, Bergman J, Haaparanta M, et al. Estimated radiation dose to the newborn in FDG-PET studies. J Nucl Med. 1996;37(2):387–93.PubMed
16.
London K, Howman-Giles R. Normal cerebral FDG uptake during childhood. Eur J Nucl Med Mol Imaging. 2014;41(4):723–35.CrossRefPubMed
17.
Chugani HT, Phelps ME. Maturational changes in cerebral function in infants determined by 18F-FDG positron emission tomography. Science. 1986;231(4740):840–3.CrossRefPubMed
18.
Chugani HT, Phelps ME, Mazziotta JC. Positron emission tomography study of human brain functional development. Ann Neurol. 1987;22(4):487–97.CrossRefPubMed
19.
Van Bogaert P, Wikler D, Damhaut P, Szliwowski H, Goldman S. Regional changes in glucose metabolism during brain development from the age of 6 years. Neuroimage. 1998;8(1):62–8.CrossRefPubMed
20.
Hays MT, Segall GM. A mathematical model for the distribution of fluorodeoxyglucose in humans. J Nucl Med. 1999;40(8):1358–66.PubMed
21.
Niven E, Nahmias C. Absorbed dose to very low birth weight infants from 18F-fluorodeoxyglucose. Health Phys. 2003;84(3):307–16.CrossRefPubMed
22.
Geyer AM, O’Reilly S, Lee C, Long DJ, Bolch WE. The UF/NCI family of hybrid computational phantoms representing the current US population of male and female children, adolescents, and adults—application to CT dosimetry. Phys Med Biol. 2014;59(18):5225–42.CrossRefPubMed
23.
Barrett PHR, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47(4):484–92.CrossRefPubMed
24.
Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol. 1980;238(1):E69–82.PubMed
25.
Hänscheid H, Fernández M, Lassmann M. The absorbed dose to blood from blood-borne activity. Phys Med Biol. 2015;60(2):741–53.CrossRefPubMed
26.
Treves ST. Pediatric nuclear medicine/PET. 3rd ed. New York NY: Springer Science + Business Media LLC; 2007.CrossRef
27.
Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50 Suppl 1:11S–20.CrossRefPubMed
Metadata
Title
Pharmacokinetic modeling of [18F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds
Authors
Kitiwat Khamwan
Donika Plyku
Shannon E. O’Reilly
Alison Goodkind
Xinhua Cao
Frederic H. Fahey
S. Ted Treves
Wesley E. Bolch
George Sgouros
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2016
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-016-0179-6

Other articles of this Issue 1/2016

EJNMMI Research 1/2016 Go to the issue

Original research

Decreased renal AT1 receptor binding in rats after subtotal nephrectomy: PET study with [18F]FPyKYNE-losartan

Original research

Imaging heterogeneity of peptide delivery and binding in solid tumors using SPECT imaging and MRI

Original research

Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide

Original research

Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response

Preliminary research

18F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma

Short communication

Test-retest analysis of a non-invasive method of quantifying [11C]-PBR28 binding in Alzheimer’s disease